Sustained-release Ophthalmology Product
This investigational ophthalmology product is an injectable drug incorporating DURECT’s sustained-release SABER® technology. The active pharmaceutical ingredient and indication have not been disclosed.
This investigational ophthalmology product is being studied for its ability to:
- Reduce injection frequency
- Lower the risk of injection-associated complications, such as injury and infection
This is an investigational product in preclinical development. It has not been approved by the FDA for marketing in the U.S. for any indication.
There are risks and uncertainties associated with our business. Please see our most recent SEC filings (10-K or 10-Q) for a complete description of these risks and uncertainties, which are incorporated herein by reference.